What is the prevalence of 19q13.11 Microdeletion Syndrome?

19q13.11 Microdeletion Syndrome is an ultra-rare chromosomal condition, with the exact global prevalence currently unknown due to limited clinical reporting and frequent underdiagnosis. While specific population-wide incidence rates have not been established in medical literature, the condition is identified through chromosomal microarray analysis, and 19 people with 19q13.11 Microdeletion Syndrome are currently registered within the DiseaseMaps.org community.

How common is 19q13.11 Microdeletion Syndrome?

19q13.11 Microdeletion Syndrome is classified as an ultra-rare disorder. Because it is a genetic deletion syndrome identified primarily through advanced genomic testing, many individuals likely remain undiagnosed or misdiagnosed with broader developmental delays. There is no established data suggesting that 19q13.11 Microdeletion Syndrome occurs more frequently in specific ethnic groups or geographic regions, and cases appear to occur sporadically across diverse populations.

What factors influence the diagnosis of 19q13.11 Microdeletion Syndrome?

The clinical presentation of 19q13.11 Microdeletion Syndrome often involves developmental delay, intellectual disability, and specific physical features, which can lead to it being overlooked in clinical settings. Challenges in determining prevalence include:

• Underdiagnosis: Many mild cases may never be referred for chromosomal microarray (CMA) testing.


• Variable Phenotype: The size and location of the deletion on the 19q13.11 region can vary, leading to a spectrum of symptom severity.


• Reporting Bias: Medical literature is often limited to case reports rather than large-scale epidemiological studies.

Are there demographic differences in 19q13.11 Microdeletion Syndrome?

Current clinical observations do not indicate a significant gender bias, as 19q13.11 Microdeletion Syndrome affects both males and females. The age of onset is pediatric, as the condition is congenital and typically identified during early childhood when developmental milestones are not met. The 19 members of the DiseaseMaps.org community provide a vital, real-world perspective that helps researchers understand the lived experience of families navigating this diagnosis, bridging the gap between clinical data and patient reality.

Next steps

• Consult a clinical geneticist to review microarray results and discuss familial implications.


• Connect with the 19q13.11 Microdeletion Syndrome community at DiseaseMaps.org to share experiences with other families.


• Maintain a detailed health record to assist specialists in monitoring the specific phenotypic expression of the syndrome.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): 19q13.11 Microdeletion Syndrome.


• Orphanet: Rare disease database for chromosomal anomalies.


• OMIM (Online Mendelian Inheritance in Man): Database of genetic conditions.


• DiseaseMaps.org: Community-reported data and patient insights.